Vireo Growth (VREOF) Cash from Operations Growth (3y) (2023 - 2026)
Vireo Growth (VREOF) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn | 13.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72.53% |
| Dec 31, 2025 | 71.55% |
| Sep 30, 2025 | -47.74% |
| Jun 30, 2025 | -15.46% |
| Mar 31, 2025 | 20.48% |
| Dec 31, 2024 | 6.16% |
| Sep 30, 2024 | 20.87% |
| Jun 30, 2024 | 90.86% |
| Mar 31, 2024 | 37.92% |
| Dec 31, 2023 | -109.91% |
| Sep 30, 2023 | 35.21% |
| Jun 30, 2023 | 32.83% |
| Mar 31, 2023 | -11.55% |